{"dataset":"Peptides.info news","version":"2026-10-03","generated":"2026-10-03","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"citation":"Twenty Residues. Peptides.info evidence dataset, version 2026-10-03. https://peptides.info/data. Licensed CC BY 4.0.","methodology":"https://peptides.info/methodology","rows":6,"data":[{"slug":"fda-import-alert-66-80-september-2026","title":"FDA widens GLP-1 import alert; adds orforglipron to the Green List","category":"regulation","status":"developing","published":"2026-10-03","updated":null,"compounds":["semaglutide","tirzepatide"],"documented":["Import Alert 66-80 (\"Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances\") was republished September 21, 2026.","FDA says that of 48 GLP-1 API sites it evaluated, 21% were noncompliant with manufacturing standards, and describes a pattern of firms registering as GLP-1 API makers, refusing records requests, then deregistering.","The Green List names firms and drugs excluded from detention. Orforglipron API was added for three manufacturers in China and one in Ireland; an orforglipron drug-product intermediate was added for one Portugal-based manufacturer.","Covered product codes include semaglutide, tirzepatide, liraglutide, exenatide, and dulaglutide, plus additional hormone and peptide codes."],"not_established":["The alert concerns bulk API entering the U.S. supply chain for compounding and manufacturing. It does not, by itself, say anything about the quality of any finished product sold to consumers.","Being absent from the Green List is not a finding of noncompliance. It means FDA has not evaluated the firm against the criteria, or the firm has not applied.","The alert is not a ban on GLP-1 imports. Listed firms continue to ship."],"would_change":"A published list of the 21% noncompliant sites, or an FDA statement connecting a specific detained shipment to a named downstream seller, would turn this from supply-chain policy into a consumer-facing story.","open_question":"If one in five inspected GLP-1 API sites fails FDA's standard, what does that imply about the API behind products that never pass through an inspected site at all?","sources":[{"grade":"primary","kind":"FDA import alert","label":"Import Alert 66-80 (FDA, published 2026-09-21)","url":"https://www.accessdata.fda.gov/cms_ia/importalert_1186.html"}],"page":"https://peptides.info/news/fda-import-alert-66-80-september-2026"},{"slug":"fda-warning-letters-five-peptide-sellers-august-2026","title":"FDA sends warning letters to five online peptide sellers in one day","category":"enforcement","status":"settled","published":"2026-10-03","updated":null,"compounds":["tirzepatide","semaglutide","retatrutide","tesamorelin","bremelanotide"],"documented":["All five letters are dated August 24, 2026 and allege the firms marketed unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act.","The Royal Peptides letter names tirzepatide, semaglutide, retatrutide, SS-31 (elamipretide), PT-141, tesamorelin, and BIMORELIN.","FDA's stated reasoning: despite 'for research use only' and 'not for human or animal consumption' labeling, website evidence established the products were intended as drugs for human use. It cites the sale of bacteriostatic water alongside a 'peptide guide' and 'peptide calculator.'","Each firm was given 15 business days to respond with corrective steps."],"not_established":["A warning letter is not a court finding, a seizure, or a shutdown order. It is FDA's allegation and a demand for a response.","The letters do not test or characterize the products. They say nothing about purity, identity, or contamination.","Five letters on one day is a visible signal, but the letters themselves do not announce a policy change or a broader sweep."],"would_change":"The firms' responses, a follow-up FDA action (seizure, injunction, consent decree), or a court ruling on whether the 'intended use' reading holds would each move this story.","open_question":"FDA's position is that a 'research use only' label is irrelevant if the surrounding context implies human use. If that reading stands, is there any way to sell a research peptide online that FDA would accept?","sources":[{"grade":"primary","kind":"FDA warning letter","label":"Royal Peptides LLC — Warning Letter 734884 (FDA, 2026-08-24)","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026"},{"grade":"primary","kind":"FDA warning letter","label":"NuScience Peptides LLC — Warning Letter 733652 (FDA, 2026-08-24)","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026"},{"grade":"secondary","kind":"Law-firm analysis","label":"McDermott Will & Emery — Federal regulators and state boards crack down on RUO peptides","url":"https://www.mcdermottlaw.com/insights/federal-regulators-and-state-boards-crack-down-on-ruo-peptides/"}],"page":"https://peptides.info/news/fda-warning-letters-five-peptide-sellers-august-2026"},{"slug":"lilly-sues-six-retatrutide-sellers-august-2026","title":"Lilly files six lawsuits over retatrutide sold before approval","category":"litigation","status":"developing","published":"2026-10-03","updated":null,"compounds":["retatrutide"],"documented":["Lilly's release names six defendants: Aesthetic Envy Cosmetic Centers (N.D. Cal.), Astra LLC d/b/a Astra Peptides (W.D. Tex.), Legendary Peptides (E.D. Tex.), Striker Pharmacy (S.D. Tex.), Texas Peptides (W.D. Tex.), and Lone Star Peptide Co. (S.D. Tex.).","Lilly states retatrutide is investigational, in Phase 3, and not approved for human use by any regulator anywhere.","Lilly says it has referred more than 200 individuals and entities to FDA, DOJ, state attorneys general, law enforcement, and licensing boards, and reported more than 14,000 listings in over 100 countries to platforms and carriers.","The release calls on payment processors, platforms, and shipping carriers to cut off sellers."],"not_established":["These are civil complaints filed by a company. No court has ruled. The release does not state the legal claims asserted (trademark, false advertising, or otherwise); the dockets do.","Lilly's release does not allege that any defendant's product was tested and found to be something other than retatrutide. It argues the sale itself is unlawful.","Nothing here addresses whether the product being sold is chemically the same as what is in Lilly's trials. That question is simply unanswered in the public record."],"would_change":"A ruling on a motion to dismiss, a settlement, a default judgment, or any docket document characterizing the products' contents.","open_question":"A drugmaker is suing to stop sales of a molecule it has not yet proven safe enough to sell itself. Who is that protecting, and does the answer change if the grey-market product turns out to be real retatrutide?","sources":[{"grade":"primary","kind":"Company press release","label":"Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (Lilly IR, 2026-08-12)","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-calls-online-platforms-payment-companies-and-regulators"},{"grade":"secondary","kind":"News report","label":"CNBC — Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide","url":"https://www.cnbc.com/2026/08/12/lilly-lawsuits-obesity-drug-retatrutide.html"}],"page":"https://peptides.info/news/lilly-sues-six-retatrutide-sellers-august-2026"},{"slug":"paradigm-peptides-owner-sentenced-70-months","title":"Paradigm Peptides owner sentenced to 70 months in federal prison","category":"enforcement","status":"settled","published":"2026-10-03","updated":null,"compounds":[],"documented":["Sentencing was announced by the U.S. Attorney's Office, Northern District of Indiana, on July 30, 2026. Kawa received 70 months' prison and one year supervised release; his sister Jennifer L. Stechkober received 16 months and one year.","Kawa pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, and to illegally importing merchandise. Both defendants were ordered to pay $78,317.52 in restitution; a $5 million money judgment was entered against Kawa.","DOJ states the business claimed FDA registration, U.S. manufacturing, and in-house testing, while in fact importing from China and India and not testing. Lab analysis found many products sold as SARMs were testosterone.","DOJ states Kawa received FDA warning letters in 2020 and 2022 and continued selling; from 2019 to 2024 the business sold to more than 54,000 customers in 50 states and over 80 countries."],"not_established":["The charges and the reported harms center on mislabeled SARMs and false claims about origin and testing. The press release does not identify any peptide product as adulterated or mislabeled.","This is one vendor. The record does not characterize the rest of the market, in either direction.","DOJ's statement that customers were 'poisoned' is the U.S. Attorney's characterization of the harm reports, not a toxicology finding stated in the release."],"would_change":"The sentencing memorandum or plea agreement, which would list the specific products and lab results, or an appeal.","open_question":"The decisive evidence in this case was that products were not what the label said. Every argument about peptides, for or against, assumes the vial contains the peptide. How often is that assumption actually checked, and by whom?","sources":[{"grade":"primary","kind":"DOJ press release","label":"U.S. Attorney's Office, N.D. Ind. — Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison (2026-07-30)","url":"https://www.justice.gov/usao-ndin/pr/illinois-man-and-indiana-woman-sentenced-respectively-70-months-and-16-months-prison"},{"grade":"secondary","kind":"News report","label":"CBS News — Judge sentences peptide vendor to nearly 6 years in prison","url":"https://www.cbsnews.com/news/peptides-seller-prison-sentence-unapproved-drugs/"}],"page":"https://peptides.info/news/paradigm-peptides-owner-sentenced-70-months"},{"slug":"fda-advisory-committee-votes-six-peptides-compounding-july-2026","title":"FDA advisory panel recommends six peptides for the compounding list, over staff objections","category":"regulation","status":"developing","published":"2026-10-03","updated":null,"compounds":["bpc-157","kpv","tb-500","mots-c","semax","epithalon"],"documented":["FDA's meeting page confirms the committee met July 23–24, 2026 to evaluate nominated bulk substances for the 503A Bulks List, and lists the seven substances and their proposed uses (e.g. BPC-157 for ulcerative colitis, KPV and TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Epitalon for insomnia, Semax for cerebral ischemia, migraine, and trigeminal neuralgia).","Reported tallies (secondary): BPC-157, KPV, and TB-500 each 8–6 with one abstention in favor; MOTS-c 7–5 with two abstentions in favor; Semax and Epitalon in favor by similar margins; emideltide rejected 7–6 with one abstention.","Reported (secondary): FDA's own reviewers had recommended against including all seven.","A favorable committee vote is advisory. Adding a substance to the 503A list requires FDA to accept the recommendation and complete notice-and-comment rulemaking. As of this writing none of the seven is on the list."],"not_established":["The vote is not an approval of any peptide for any use, and does not make compounding them legal today.","A recommendation for the bulks list is a judgment about whether pharmacists may compound a substance for individual prescriptions. It is not a finding that the substance works for the nominated use.","The official vote record is not on FDA's meeting page as of our review. The tallies above come from reporting, and we grade them accordingly."],"would_change":"FDA posting the official meeting minutes or vote summary, a proposed rule adding any of the six, or a public FDA statement declining to follow the committee.","open_question":"An advisory panel voted narrowly to let pharmacists compound peptides that FDA's own scientists said lacked human efficacy data. Is this access winning over evidence, or evidence standards failing to keep up with what people are already using? Both camps claim this vote.","sources":[{"grade":"primary","kind":"FDA meeting notice","label":"July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (FDA)","url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"},{"grade":"secondary","kind":"Trade-press report","label":"AJMC — FDA Panel Backs 6 Peptides for Compounding (2026-07-31)","url":"https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding"},{"grade":"secondary","kind":"Trade-association report","label":"NCPA — FDA advisory committee nominates six peptides for pharmacies to compound (2026-07-31)","url":"https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound"}],"page":"https://peptides.info/news/fda-advisory-committee-votes-six-peptides-compounding-july-2026"},{"slug":"retatrutide-triumph-1-phase-3-topline","title":"Retatrutide Phase 3: 28.3% mean weight loss at 80 weeks, 11.3% quit the top dose","category":"clinical","status":"developing","published":"2026-10-03","updated":null,"compounds":["retatrutide"],"documented":["TRIUMPH-1 (NCT05929066) is an 80-week, randomized, double-blind, placebo-controlled Phase 3 trial in adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes.","Efficacy-estimand mean weight change at 80 weeks: −19.0% (4 mg), −25.9% (9 mg), −28.3% (12 mg), −2.2% (placebo). The treatment-regimen estimand, which counts people who stopped, reads −17.6%, −23.7%, −25.0%, and −3.9%.","45.3% of the 12 mg group lost at least 30% of body weight, versus 0.5% on placebo. In a pre-specified extension of 532 participants with BMI ≥35, the 12 mg-to-maximum-tolerated-dose arm reached −30.3% at 104 weeks.","Most common adverse events at 12 mg vs placebo: nausea 42.4% vs 14.8%, diarrhea 32.0% vs 13.5%, vomiting 25.3% vs 4.8%. Dysesthesia 12.5% vs 0.9%. Discontinuation due to adverse events: 4.1%, 6.9%, 11.3% across doses vs 4.9% on placebo.","Results are topline, from a company release. Lilly says full results will be presented at medical meetings and published in peer-reviewed journals."],"not_established":["Topline means the sponsor's summary. The trial has not been peer-reviewed, and the full adverse-event tables, dropout patterns, and subgroup results are not public.","Weight loss at 80 weeks says nothing yet about what happens after stopping, cardiovascular outcomes, or safety over years. Those are separate trials (TRIUMPH-2, -3, and an outcomes study).","Retatrutide is not approved anywhere. Anything sold under that name today is outside this trial and outside this evidence."],"would_change":"Peer-reviewed publication of TRIUMPH-1, topline results from TRIUMPH-2 and -3, or a regulatory submission.","open_question":"The 12 mg arm produced surgery-level weight loss and more than one in ten participants stopped because of side effects. Is the right dose the one that works best or the one most people can stay on? The 4 mg arm, with a lower dropout rate than placebo, is the quiet half of this release.","sources":[{"grade":"primary","kind":"Company press release","label":"Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (Lilly IR, 2026-05-21)","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss"},{"grade":"primary","kind":"Trial registry","label":"NCT05929066 — TRIUMPH-1 (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT05929066"}],"page":"https://peptides.info/news/retatrutide-triumph-1-phase-3-topline"}]}